Atherectomy devices refer to the medical devices used to treat atherosclerosis by removing plaque from arteries. According to Marketstack, the Global Atherectomy Devices Market is expected to grow considerably during the forecast period. Factors such as the Surging volume of patients suffering from targeted diseases such as Peripheral Artery Diseases (PADs) and Coronary Artery Diseases (CADs) are expected to drive the Global Atherectomy Devices Market in the forecasted period. Further, the increasing usage of drug-coated balloons and the surging demand for minimally invasive procedures is expected to drive the Global Atherectomy Devices Market in the forecasted period. Furthermore, the innovations and advancements of technologies provided by the different market players currently established, which are focused on constant upgradations of technologies to enhance the quality of healthcare being provided to other patients, are projected to drive the Global Atherectomy Devices Market in the forecasted period. However, high capital investments in laser-related Atherectomy devices and procedure-related risks such as increased risk of distal embolization and arterial perforation may restrict the Atherectomy devices market in the forecasted period.

Atherectomy is based on acquiring a significant lumen by clearing plaque and calcified lesions from the artery, which helps restore the blood flow of arteries. They are widely used in applications such as cardiovascular, neurovascular and peripheral vascular.

The surging number of patients with cardiovascular disease is driving the market's growth. Peripheral artery disease and coronary artery disease are both conditions that involve the buildup of plaque within arteries, which can narrow and harden the blood vessels, leading to minimized blood flow and potentially severe health complications. The surging prevalence of cardiovascular diseases, the increasing geriatric population, and the trend towards minimally invasive treatments drive the atherectomy devices market. Atherosclerosis & other cardiovascular conditions are the leading causes of morbidity & mortality worldwide. The ageing population is more exposed to these diseases due to age-related changes in arterial fitness. The growing geriatric population drives the demand for atherectomy devices. Technological advancements in atherectomy devices have made procedures safer and more effective, attracting healthcare providers and physicians to adopt atherectomy procedures. Increasing awareness and diagnostic capabilities contribute to the growing demand for atherectomy procedures, with timely detection and accurate diagnosis of atherosclerotic lesions enabling healthcare providers to recommend appropriate interventions. Overall, these factors contribute to the growing demand for atherectomy procedures as an effective treatment option for atherosclerosis, driving innovation in device development. Traditionally, open surgery has been used to address plaque buildup, which is invasive, hazardous, and takes a long time to recover. However, atherectomy devices have allowed doctors to undertake less intrusive treatments that enable speedier recovery times and decreased risk of complications. In addition, atherectomy devices have the potential to increase drug efficacy by evaluating the use of orbital atherectomy to treat CAD in patients who are not eligible for Coronary Artery Bypass (CAB) grafting and assess the use of rotational atherectomy to treat PAD in patients who are not qualified for Endovascular Therapy (EVT). The results of these clinical trials are expected to demonstrate the potential of atherectomy devices further and could lead to their wider adoption in the treatment of cardiovascular diseases.

North America is predicted to hold a significant share of the market. The increasing availability of compensate for atherectomy systems, acquiring of atherectomy systems among medical professionals, the large patient population of coronary and peripheral artery diseases, and an rising number of clinical trials (that help to evaluate the therapeutic efficacy of atherectomy systems in specific disease treatment) are fueling the development of the North American atherectomy devices market. The growing preference for minimally invasive surgical processes is a significant market driver for atherectomy devices. These procedures povides several advantages over traditional open surgeries, such as reduced trauma, faster recovery, lower complication rates & reduced healthcare costs. Patients and healthcare providers appreciate the quicker recovery, reduced postoperative pain, and shorter hospital stays associated with minimally invasive procedures. Technological advancements have also improved the effectiveness and safety of atherectomy procedures, making them more appealing to patients and healthcare providers. Patient-centric care and shared decision-making processes prioritize patient preferences, leading to healthcare providers offering atherectomy procedures and driving the demand for atherectomy devices. As the need for minimally invasive procedures continues to rise, the market for atherectomy devices is expected to grow, with manufacturers investing in R&D to meet the evolving demands of patients & healthcare providers. Technological advances significantly contribute to the growth and adoption of atherectomy devices, driving innovation, improving device performance, and enhancing patient outcomes. Improved device design and performance, minimally invasive approaches, combination therapies, imaging and navigation technologies, and the integration of robotics and AI offer reduced patient discomfort, shorter hospital stays, faster recovery times, and lower healthcare costs. Combination therapies, such as angioplasty, stenting & drug delivery systems, offer synergistic benefits in treating atherosclerosis, reducing restenosis risk, and optimizing patient outcomes. Integrating robotics and AI technologies in atherectomy devices provides promising opportunities for improved precision, stability, and control. Technological advancements in the atherectomy devices market offer the chance to increase the market further.

The market key players are Avinger Inc., Becton, Dickinson and Company, Medtronic plc, and Invamed Medical.

In February 2023, Abbott and Cardiovascular Systems, Inc. (CSI) announced a definitive acquiescence for Abbott to achieve CSI, a medical device company with an innovative atherectomy system utilized in treating peripheral and coronary artery disease. Under the terms of the agreement, CSI stockholders will collect $20 per common share at a total awaited equity value of approximately $890 million.

Global Atherectomy Devices Market report provides deep insight into the Industrial market's current and future state across various regions. The study comprehensively analyses the Atherectomy Devices Market by segmenting based on Product (Directional Atherectomy Systems, Orbital Atherectomy Systems, Photo-ablative (Laser) Atherectomy Systems, and Rotational Atherectomy Systems), Application (Peripheral Vascular Applications, Cardiovascular Applications, and Neurovascular Applications), End User (Hospitals and Surgical Centers, Ambulatory Care Centers, and Other End Users), and Geography (Asia-Pacific, North America, Europe, South America, and Middle East & Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers emerging market trends, development, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with prominent companies and profiles, including their market shares and projects.